FI904867A0 - Komposition och foerfarande foer oekande av upploesningshastigheten foer blodkoagulat. - Google Patents

Komposition och foerfarande foer oekande av upploesningshastigheten foer blodkoagulat.

Info

Publication number
FI904867A0
FI904867A0 FI904867A FI904867A FI904867A0 FI 904867 A0 FI904867 A0 FI 904867A0 FI 904867 A FI904867 A FI 904867A FI 904867 A FI904867 A FI 904867A FI 904867 A0 FI904867 A0 FI 904867A0
Authority
FI
Finland
Prior art keywords
foer
blodkoagulat
composition
over
farand
Prior art date
Application number
FI904867A
Other languages
English (en)
Other versions
FI102812B (fi
FI102812B1 (fi
Inventor
Guy L Reed
Gary R Matsueda
Edgar Haber
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of FI904867A0 publication Critical patent/FI904867A0/fi
Application granted granted Critical
Publication of FI102812B publication Critical patent/FI102812B/fi
Publication of FI102812B1 publication Critical patent/FI102812B1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Surgical Instruments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
FI904867A 1988-04-04 1990-10-03 Menetelmä 2-antiplasmiinin monoklonaalisen vasta-aineen valmistamiseksi FI102812B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17722288A 1988-04-04 1988-04-04
US17722288 1988-04-04
PCT/US1989/001065 WO1989009817A1 (en) 1988-04-04 1989-03-15 Composition and method for acceleration of clot lysis
US8901065 1989-03-15

Publications (3)

Publication Number Publication Date
FI904867A0 true FI904867A0 (fi) 1990-10-03
FI102812B FI102812B (fi) 1999-02-26
FI102812B1 FI102812B1 (fi) 1999-02-26

Family

ID=22647707

Family Applications (1)

Application Number Title Priority Date Filing Date
FI904867A FI102812B1 (fi) 1988-04-04 1990-10-03 Menetelmä 2-antiplasmiinin monoklonaalisen vasta-aineen valmistamiseksi

Country Status (15)

Country Link
EP (1) EP0336693B1 (fi)
JP (1) JP2871775B2 (fi)
KR (1) KR100194113B1 (fi)
AT (1) ATE114480T1 (fi)
AU (1) AU628041B2 (fi)
CA (1) CA1341377C (fi)
DE (1) DE68919504T2 (fi)
DK (1) DK174062B1 (fi)
ES (1) ES2064435T3 (fi)
FI (1) FI102812B1 (fi)
GR (1) GR3015182T3 (fi)
HU (1) HU207349B (fi)
NO (1) NO301374B1 (fi)
WO (1) WO1989009817A1 (fi)
ZA (1) ZA892464B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JPH02268694A (ja) * 1989-04-07 1990-11-02 Teijin Ltd 血栓溶解剤
JP2001515345A (ja) * 1996-09-20 2001-09-18 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対する抗体を用いてフィブリン溶解を増進するための組成物と方法
US6524675B1 (en) 1999-05-13 2003-02-25 3M Innovative Properties Company Adhesive-back articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735340B2 (ja) * 1985-05-23 1995-04-19 帝人株式会社 血栓溶解促進剤
DE3751907T2 (de) * 1986-05-15 1997-04-03 Univ Emory Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie

Also Published As

Publication number Publication date
JP2871775B2 (ja) 1999-03-17
KR100194113B1 (ko) 1999-06-15
DK174062B1 (da) 2002-05-13
HU892304D0 (en) 1991-07-29
ES2064435T3 (es) 1995-02-01
AU628041B2 (en) 1992-09-10
FI102812B (fi) 1999-02-26
ATE114480T1 (de) 1994-12-15
NO301374B1 (no) 1997-10-20
EP0336693A3 (en) 1990-03-21
HU207349B (en) 1993-03-29
AU3284589A (en) 1989-11-03
NO904294L (no) 1990-12-04
WO1989009817A1 (en) 1989-10-19
DE68919504D1 (de) 1995-01-12
GR3015182T3 (en) 1995-05-31
JPH03504717A (ja) 1991-10-17
DE68919504T2 (de) 1995-06-29
ZA892464B (en) 1989-12-27
EP0336693B1 (en) 1994-11-30
DK240190A (da) 1990-10-04
NO904294D0 (no) 1990-10-03
EP0336693A2 (en) 1989-10-11
HUT56394A (en) 1991-08-28
DK240190D0 (da) 1990-10-04
KR900700129A (ko) 1990-08-11
FI102812B1 (fi) 1999-02-26
CA1341377C (en) 2002-07-16

Similar Documents

Publication Publication Date Title
Lijnen et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
AP9701004A0 (en) Low molecular weight bicyclic thrombin inhibitors.
FI904867A0 (fi) Komposition och foerfarande foer oekande av upploesningshastigheten foer blodkoagulat.
NO910811D0 (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
BR9708859A (pt) Composto uso do mesmo composição para inibir formação de trombo em sangue e processos para inibir trombina e formação de agregados de plaquetas sanguíneas e de trombo no sangue para tratar ou evitar tromboemolismo venoso e embolismo pulmonar trombose tromboembolismo cardiogênico acidente vascular cerebral trombose angina instável infartação miocárdica aterosclerose distúrbio cardaco isquêmico reoclus o restenose oclus o de enxertos de derivação de artéria coronária e doença cerebrovascular oclus
FI885331A0 (fi) Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli.
Kowalski et al. Circulating fibrinogen degradation products (FDP) in dog blood after intravenous thrombin infusion
Hara et al. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits
ATE238803T1 (de) Pphospholipidkomplexe von proanthocyanidin a2 als antiatherosklerotische mittel
Marci et al. A review of the clinical indications for the plasma heparin assay
Eisenberg Role of new anticoagulants as adjunctive therapy during thrombolysis
Violi et al. Effects of ticlopidine on platelet function and blood coagulation
Lijnen et al. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis
Mirshahi et al. Effect of heparin and enoxaparin on platelet interaction with fibrin clots
Gurevitz et al. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model
Henriksson et al. Fatal iron intoxication with multiple coagulation defects and degradation of factor VIII and factor XIII
Jang et al. A randomized, blinded study of two doses of Novastan®(brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study
ATE113983T1 (de) Gewebeplasminogenaktivator mit fibrin- spezifischen eigenschaften.
Meddahi et al. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Preissner et al. Influence of fibrinogen on fibrin polymerization. Ultracentrifugation studies
Diffang et al. The effect of alpha-blocking agents on the amount of intravascular fibrin in the lungs during induced intravascular coagulation in rats
Mombelli et al. Low Grade DIC in Liver Cirrhosis: Fact or Fiction?-Rebuttal
DK0563280T3 (da) Vævsplasminogenaktivator substitutionsvariant
Grannis et al. Prothrombin and antithrombin: their opposing functions in blood coagulation
WO1995030438A3 (en) Methods and compositions to enhance endogenous fibrinolytic activity

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: THE GENERAL HOSPITAL CORPORATION

MA Patent expired